Metrics as of 10/15/2026, 10:21 PM (Berlin time), refresh in progress.
Context Therapeutics Stock
Context Therapeutics Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Martin A. Lehr
- Employees
- 15
- Market cap
- $22 M
- IPO
- 20/10/2021
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a…
Context Therapeutics stock: price history
1D
-5.9%
1W
-19.6%
1M
-34.0%
6M
-89.5%
YTD
-83.6%
1Y
-82.1%
2Y
-87.7%
5Y
–
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~7% stronger price swings than usual
Ask the agents about Context Therapeutics
Analyst assessment of Context Therapeutics
PRICE TARGET LOW
US$4.50
CONSENSUS
US$5.25
MEDIAN
US$5.25
PRICE TARGET HIGH
US$6.00
0
STRONG BUY
6
BUY
0
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 16/06/2026
Context Therapeutics stock metrics
P/E
-0.5
P/B
0.6
EV/EBITDA
0.45
RETURN ON EQUITY
-38.1%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
69.4%
FLOAT SHARES
63,733,829
AVG. DAILY VOLUME (30D)
1,052,818
Institutional holders
Comparable stocks
Frequently asked questions about Context Therapeutics stock
What does Context Therapeutics do?
Context Therapeutics Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Martin A. Lehr, the company employs around 15 people.
The IPO was on 20/10/2021; the stock trades on NASDAQ under the ticker CNTX.
What do analysts say about Context Therapeutics stock?
6 analysts rate the stock, the consensus is Buy (as of 16/06/2026).
The average price target is US$5.25, ranging from US$4.50 to US$6.00, with a median of US$5.25.
This is an external assessment, not a statement by Market Jury.
When does Context Therapeutics report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 7% stronger than usual.
Does Context Therapeutics pay a dividend?
No, Context Therapeutics currently does not pay a dividend.
Which stocks are comparable to Context Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Context Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Context Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.